Loading...
A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Nature Publishing Group
1992
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1977612/ https://ncbi.nlm.nih.gov/pubmed/1313691 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|